The complaint, filed by the DJS Law Group, targets statements made by Zoetis between January 14, 2025, and May 6, 2026. Plaintiffs allege that the company issued false and misleading information concerning its prominent veterinary products, specifically Librela, Apoquel, and Cytopoint. These claims suggest that the company concealed operational difficulties within these segments, potentially inflating share value before the truth emerged.
Investors who purchased ZTS stock during the specified timeframe are now eligible to participate in the recovery efforts. The deadline for shareholders to seek appointment as a lead plaintiff is July 27, 2026. While the DJS Law Group is actively recruiting participants, they emphasize that shareholders are not required to serve as lead plaintiffs to remain part of the class action recovery. The firm, headed by David J. Schwartz, specializes in securities litigation and is currently managing the outreach for those seeking to recoup losses linked to the alleged market deception.
Comments (0)
No comments yet. Be the first!